Kornimate/medical-research-clean huggingface dataset:
community-acquired pneumonia in buskerud county in norway

Conditions: Community-Acquired Infections; Pneumonia

Summary: the purpose of this study is to determine the etiology of community-acquired pneumonia, to assess risk factors and to investigate potential prognostic biomarkers of serious disease and fatal outcome.

background: this project addresses an important challenge in international medicine: pneumonia as the leading cause of death from infection in developed countries. purpose: (a) determine the etiology of cap among adult hospitalized patients- especially the occurrence of mixed infections- by systematic implementation of combined conventional and new diagnostic methods. (b) assess risk factors of cap, such as copd, congestive heart failure, smoking, malignancy etc., predictive of re-admittance to hospital and mortality. (c) examine the prognostic value of potential predictors in relation to all-cause mortality in adult patients hospitalized with cap. design: prospective observational study with inclusion of 270 adult patients during a 3-year period, who all required admission for pneumonia in a community hospital setting. clinical and biochemical data was recorded longitudinally by inclusion, at stable clinical situation and after 6 weeks, and mortality and need for re-admission within 12 months. patients were examined systematically, using modern research methods to explore relevant microbes. at all points, blood tests were sampled for clinical-chemical analysis, dna, rna and immunological analyses. application: a translational research approach with the ambitions to elucidate new pathogenic mechanisms which could lead to new diagnostic tools and treatment modalities. this will possibly lead to less drug exposure and unnecessary hospitalization both of which have positive consequences for patients and medical care costs.

Eligibility criteria:
inclusion criteria: * new infiltrate on chest x-ray and * fever \> 38,0 by rectal measurement * at least one of these additional criteria: cough +/- expectoration, dyspnoea, respiratory chest pain, crackles or reduced respiratory sounds. * criteria must be present within 48 hours after admission exclusion criteria: * patients \< 18 years * non infectious cause of lung infiltration (tumors, embolism) * bronchial obstruction (tumor, bronchiectasia) * hospitalised more than 48 hours or discharged within the last 2 weeks

Keywords: community-acquired infections pneumonia/microbiology pneumonia/diagnosis prognosis prospective studies
topical antifungal treatment for tinea cruris

Conditions: Tinea Cruris

Summary: to determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris


Eligibility criteria:
inclusion criteria: * moderate erythema, mild scaling, and moderate pruritis exclusion criteria: * pregnancy and allergies

Keywords: tinea cruris, antifungal
prospective multicenter trial to explore the tolerability and safety of the h-coil deep tms in combination with serotonin selective reuptake inhibitor(ssri)

Conditions: Major Depressive Disorder, Recurrent, Unspecified; Major Depressive Disorder, Single Episode, Unspecified

Summary: the purpose of the study is to explore the tolerability and safety of the h-coil deep transcranial magnetic stimulation (tms) in combination with serotonin selective reuptake inhibitor (ssri) for subjects with major depression disorder (mdd) who complete/ discontinued the deep tms multicenter study for subjects with major depression disorder (mdd) (protocol# ctp-0001-00).


Eligibility criteria:
inclusion criteria: * outpatients * men and women 22-68 years of age * primary dsm-iv diagnosis of major depression, single or recurrent episode confirmed by the structured clinical interview for the dsm-iv (scid-iv). * completed the ctp-0001-00 study according to the protocol, i.e., either completed 16 weeks of treatment, or were discontinued from the ctp-0001-00 study protocol after 6 weeks or more from randomization. * capable and willing to provide informed consent. * able to adhere to the treatment schedule. exclusion criteria: * discontinued from ctp-0001-00 study protocol due to the following reasons: tolerability and safety reason, non-compliant with the study protocol, developed documented suicidal ideation as assessed by the investigator or significant suicide risk based on hdrs-21 item 3 score of 3 or 4 or suicidal attempt * current psychotic disorder * sensitivity or allergic or other severe adverse event previously reported for citalopram, escitalopram, fluoxetine, paroxetine, or sertraline. * known or suspected pregnancy * women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse. * minimal mt found for both hands is higher than 75% of stimulator power output.

Keywords: depression mdd ssris tms
investigation of an adaptive treatment algorithm for post-op thoracic patients to reduce the length of drainage

Conditions: Pulmonary Fistula

Summary: the purpose of this study is to reduce the length of drainage using a treatment protocol to control the manipulation of the applied vacuum to the pleural cavity.

in this prospective study, a treatment algorithm is tested in a subgroup of patients with postoperative pulmo-pleural fistula. the primary aim is to reduce the duration of pulmo-pleural fistulation. secondary aim is to reduce the duration of chest tube therapy.

Eligibility criteria:
inclusion criteria: * patients with a post operative air leak after 16 to 24 hours bigger than 50ml/min. exclusion criteria: * patients with an empyema * patients with a spontaneous pneumothorax

Keywords: algorithm treatment protocol thoracic drainage device
dose-response study of mr-107a-01 in the treatment of post-surgical dental pain

Conditions: Pain; Postoperative Pain; Pain, Acute

Summary: mr-107a-01 is being studied to investigate its efficacy, safety, and dose-response after dental surgery.


Eligibility criteria:
inclusion criteria: 1. males and females ≥18 years of age. 2. requirement for dental surgery for extraction of ≥2 x third molars, at least 1 of which involves partial or complete mandibular bony impaction. 3. pain intensity (pi) using a numeric pain rating scale (nprs) ≥5 during the 5 hours following the end of surgery. 4. rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery. exclusion criteria: 1. previously dosed with mr-107a-01. 2. subject with known hypersensitivity to nonsteroidal antiinflammatory drugs (nsaids). 3. active gi bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., crohn's disease or ulcerative colitis, bleeding disorders that may affect coagulation. 4. use of any investigational drug within 28 days, or 5 half-lives, prior to screening whichever is longer. 5. use of medications with the potential to interact with mr-107a-01. 6. other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
trial of laparoscopic cholecystectomy vs. non-operative treatment for gallbladder dyskinesia

Conditions: Gallbladder Dyskinesia

Summary: the goal of this study is to challenge the existing clinical practice of employing laparoscopic cholecystectomy as the treatment for gallbladder dyskinesia by comparing it to a regimen of active non-surgical therapy.

willing and eligible patients will be enrolled into the trial and randomized to surgical vs non-surgical treatment following informed consent. the following information will be collected over the next 18 months: age,race, sex, baseline and follow-up quality of life quationnaire scores, a complete medical history, including co-morbid illnesses, medications and surgical history, and a complete assessment of symptoms, including disease specific symptoms against the rome iii criteria for functional gallbladder disorder. patients randomized to surgery will be referred for immediate laparoscopic cholecystectomy. patients in the non-surgical management group will be counseled on maintenance of a low-fat diet, and provided with a prescription for amitriptyline 25mg once daily. patients with persistent, non responsive symptoms that fail to respond to at least one week of administration of amitriptyline will be allowed to voluntarily, cross over into the surgically treated group. after randomization, certain data collection points will be unique to the two groups. these are as follows and are in addition to the general data which will be collected from both groups: surgery group: operative/pathology findings \& operative complications non-surgical group: patients will be asked to maintain a food diary and a symptom diary. patients will be asked to report any medication related side effects. both groups will receive a phone call for assessment of conditions. non-surgical groups will be asked to report any medication related side effects. follow-up for both groups will continue throughout the 18 month period. in addition to the monthly calls, patients will be contacted every three months after their initial treatment to take the sf-8 questionnaire and obtain an assessment of symptoms using the rome iii criteria.

Eligibility criteria:
inclusion criteria: patients with a normal gallbladder patients with symptoms compatible with gallbladder dyskinesia (functional gallbladder disorder) as defined by the rome iii criteria patients with a cholecystokinin hepatobiliary (cck-hida) scintigraphy gallbladder ejection fraction of \<38%, performed at a facility using updated society of nuclear medicaine guidelines for test administration exclusion criteria: patients with other known sources of chronic abdominal pain (ex: crohn's disease) patients with chronic narcotic use which will affect the reproducibility and validity of the cck-hida results patient with a history of allergy to amitriptyline patients with a seizure disorder
phase i/ii clinical study to evaluate vb15010 tablets in patients with advanced solid tumors

Conditions: Cancer; Neoplasms; Neoplasms, Breast; Tumor; PARP; Ovarian Neoplasms; Prostatic Cancer; Pancreatic Cancer; Breast Cancer; Biliary Cancer; Colorectal Cancer

Summary: this research is designed to determine if experimental treatment with parp1 inhibitor, vb15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * age ≥ 18 at the time of screening; * histological or cytological confirmation of advanced malignancy ; * progressive cancer at the time of study entry; * adequate organ and marrow function as defined by the protocol; * homologous recombination repair gene mutation. exclusion criteria: * major surgery within 4 weeks of the ﬁrst dose of study treatment. * spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. patients with leptomeningeal carcinomatosis are excluded. * patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (mds)/acute myeloid leukaemia (aml).

Keywords: vb15010 parp ovarian cancer prostatic cancer pancreatic cancer breast cancer biliary cancer
noacs in oral and maxillofacial surgery: impact on post-operative complications

Conditions: Surgery, Oral; Hemorrhage; Postoperative Complications; Oral Surgical Procedures; Anticoagulants Causing Adverse Effects in Therapeutic Use; Anticoagulant-induced Bleeding

Summary: aims: to investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with doacs. to investigate the perioperative and postoperative bleeding volume during oral surgical procedures in patients medicated with doacs. to examine whether increased perioperative bleeding volume complicates the planned intervention, thereby prolonging the operation time. previous studies have shown that the incidence of healthcare-consuming bleeding complications following oral surgical procedures in patients who are prescribed warfarin is approximately 4% (9). to investigate whether the incidence is higher or lower by the intake of doac it is considered to be sufficient with 100 patients in each group. the groups consist of patients who are prescribed warfarin, doacs, as well as a control group. hypothetical outcomes: the incidence of bleeding complications and the perioperative and postoperative bleeding volume during oral surgical procedures in patients medicated with doacs are higher compared to patients medicated with warfarin and patients taking no anticoagulants. increased perioperative bleeding volume complicates the planned intervention, thereby prolonging the operation time. clinical relevance: the study will serve as a basis for the development of treatment guidelines for patients who medicate with doacs. if it turns out that the oral surgery procedure presents no increased risk of complications and that the bleeding volume does not complicate the surgery significantly, it may be recommended that patients who medicate with doacs whom are in need of oral surgical procedures seek ordinary dental care.

the continuous variables (amount of bleeding during surgery) will be analyzed with linear regression if they show normal distribution patterns. the ordinal variables (postoperative bleeding complications) will be analyzed with ordinal logistic regression. dichotomous variables (presence of other postoperative complications) will be analyzed with logistic regression.

Eligibility criteria:
inclusion criteria: need of dental extraction / oral surgery, and medication with: 1. warfarin or 2. doacs or 3. no treatment or ak-platelet therapy and age-matched to group a) and b). exclusion criteria: medication with the combination of anticoagulants and antiplatelet ongoing drug abuse
changes inmpod after full-thickness macular hole closure

Conditions: Full Macular Hole

Summary: the notable increase in mpod following successful surgery suggests its potential role as a valuable adjunctive biomarker associated with a good visual prognosis following this type of macular hole surgical interventions.

full-thickness macular hole (ftmh) is a debilitating retinal disorder, particularly in its advanced forms, necessitating surgical intervention for vision restoration. this study showes the successful closure of a large ftmh using the inverted flap technique, highlighting the essential role of multimodal imaging, and particularly of macular pigment optical density (mpod) assessment, in preoperative and postoperative evaluation. surgery was performed by an expert vitreoretinal surgeon, resulting in significant postoperative improvements in visual acuity and retinal architecture. multimodal imaging, including mpod assessment, played a pivotal role in preoperative evaluation and postoperative monitoring.

Eligibility criteria:
inclusion criteria:age older than 60 years * diagnosis of fthm * absence of other ocular diseases, responsible for macular edema (retinal vein occlusion, diabetic retinopathy, age-related macular degeneration exclusion criteria: no diagnosis of pseudophakic cystoid macular oedema * previous treatment for pseudophakic cystoid macular oedema * presence of other ocular diseases, responsible for macular edema (retinal vein occlusion, diabetic retinopathy, age-related macular degeneration)
effect of time-restricted eating on cognitive function and other biopsychosocial factors in menopausal women undertaking a 12-week exercise programme

Conditions: Menopause; Cognitive Deficits, Mild

Summary: the goal of this quasi-experimental study is to test effect of time-restricted eating on cognitive function and other biopsychosocial factors in menopausal women undertaking a 12-week exercise programme. the main questions to answer are: 1. what is effect of time-restricted eating on cognitive function in menopausal women undertaking a 12-week exercise programme? 2. what is effect of time-restricted eating on menopausal symptoms in menopausal women undertaking a 12-weeks exercise programme? 3. what is effect of time-restricted eating on metabolic health parameters in menopausal women undertaking a 12-weeks exercise programme? participants of both groups will have moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks. participants of one of two groups will not only exercise but also have a time-restricted eating following 16:8 protocol for 12 weeks. participants will have pre-tests and post-tests: * blood samples collection (to measure level of brain-derived neurotrophic factor, glial cell derived neurotrophic factor, insulin, glucose, lipid profile), * body composition analysis, * stroop test and n-back test, * electroencephalography using emotiv epic x devices, * one-repetition maximum test, ruffier test, * questionnaire assessment (using menopause rating scale and the menopause-specific quality of life questionnaire). researchers will compare two groups - exercise group and combination group which will do both time-restricted eating and exercise to see if there is a modulating effect of time-restricted eating in participants undertaking exercise.


Eligibility criteria:
inclusion criteria: * perimenopause, menopause or post-menopause * lightly physically active or physically inactive exclusion criteria: * using hormone replacement therapy or hormonal contraception * having significant contraindications to physical exercise or time-restricted eating
clinical trial comparing two non-surgical treatments for severe blepharoptosis

Conditions: Blepharoptosis; Ptosis, Eyelid; Myasthenia Gravis; Stroke; Traumatic Brain Injury; Chronic Progressive External Ophthalmoplegia

Summary: this clinical trial will evaluate two non-surgical devices designed to improve eye lid opening for patients with severe blepharoptosis (incomplete opening of the eyelids).

two non-surgical devices for patients with blepharoptosis will be evaluated. the magnetic levator prosthesis (mlp), is an external device that makes use of a newer class of permanent magnets (made of alloys of neodymium (nd), iron (fe) and boron (b)) to restore eyelid movement. the kinesiotape frontalis sling (ktfs), involves the use of tape to help facilitate levator muscle contraction to open the eyelid. video recordings of spontaneous and volitional blinks will be used to evaluate the effects of each device on eyelid reanimation. the clinical trial will employ a crossover design in which participants will try each device at home in counterbalanced order with a washout period between. in each period of the crossover, participants will receive training (during study visits at massachusetts eye and ear) in how to apply the device and will then try the device at home for one week with daily follow up by video calls. at the end of the one-week period of home use there will be a study visit at massachusetts eye and ear when the device will be returned and additional video recordings of eye blinks will be made. at the end of the crossover period, participants will be asked to complete a questionnaire comparing the two devices and to select their preferred device.

Eligibility criteria:
inclusion criteria: * presence of ptosis for at least one eye which occludes the visual axis in the resting position (without frontalis drive, lifting with forehead muscles) * moderate cognitive function or better defined as greater than or equal to 18 out of 30 on a pre-screening of the mini-mental state exam (mmse) exclusion criteria: * absence of ptosis which occludes the visual axis * presence of a corneal ulcer of any size * age less than 5 years * severe cognitive impairment defined as mmse score less than 18, behaviors consistent with delirium (combinations of disorientation, hallucinations, delusions, and incoherent speech), or lethargy. * presence of corneal hypoaesthesia; * orbicularis weakness on the side of the ptosis * mechanical ptosis, including ptosis due to orbital or lid tumor, cicatricial processes affecting the movements of the upper lid, and enophthalmos. * previous ptosis surgery less than 3 months prior to visit 1. * lid position affected by lid or conjunctival scarring. * history of herpes keratitis. * periocular neurotoxin (eg, botox, xeomin, dysport, myobloc) injections on the side of the ptosis within 3 months prior to visit 1 and during the study. * history of hyperthyroidism or thyroid eye disease (ie, exophthalmos, upper eyelid retraction, diplopia secondary to extraocular muscle involvement). hypothyroidism that is controlled on medication is allowed
a comparison of hearing aid fitting methods

Conditions: Hearing Loss

Summary: this investigation will compare hearing aid fitting methods between self-fitting and clinician fitting approaches by using a standardized questionnaire to evaluate subjective hearing aid benefit.

participants will be fit with hearing aids using two different fitting methods (fitting a and fitting b). the order of the fitting will be randomized such that half of the participants will start out with fitting a and half of the participants will start out with fitting b. all participants will undergo baseline speech testing and answer a questionnaire about their experiences in daily life without hearing aids. all participants will use devices for a period of 1-2 weeks in their daily lives. after this first home trial, participants will return to the clinic where they will answer questionnaires regarding their experience with the devices. they will also perform aided speech testing. they will then be given devices with the second fitting method and will wear devices for a period of 1-2 weeks in their daily lives. following the second home trial, all participants will return to the clinic to answer the same questionnaire that was given after home trial #1, and complete aided speech testing. the results for each of the two fitting methods will be analyzed.

Eligibility criteria:
inclusion criteria: * mild to moderate bilateral hearing loss * first time (new) hearing aid users or experienced hearing aid users * ability to use a smartphone * fluent in english; ability to read and write in english * willing and able to provide informed consent exclusion criteria: * self reported ear-related pathology including otorrhea within 90 days, dizziness, sudden onset or worsening of hearing loss within 90 days, visible deformity of the ear, otalgia * unilateral hearing loss * chronic, severe tinnitus